Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Chinese patients
ICOS
ICOSL
lung adenocarcinoma
prognostic factor
Journal
Animal models and experimental medicine
ISSN: 2576-2095
Titre abrégé: Animal Model Exp Med
Pays: United States
ID NLM: 101726292
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
11
08
2023
accepted:
27
09
2023
medline:
31
10
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Immunotherapy has become the fastest-adopting treatment paradigm for lung cancer with improved survival. By binding with its ligand (inducible T-cell co-stimulator and its ligand [ICOSL]), an inducible T-cell co-stimulator (ICOS) could contribute to reversing immunosuppression and improving immune response and thus be a potential target for cancer immunotherapy. We selected 54 formalin-fixed, paraffin-embedded tumor tissues from cases with stage I-III lung adenocarcinoma cancer. Immunohistochemical expression of ICOS and ICOSL was evaluated. The correlation with clinical parameters in Chinese patients was also compared with TCGA results. The positive rates of ICOS and ICOSL were 68% and 81.5%, respectively, in lung tumor tissues. Of these, 9 cases had a low expression of ICOS, and 22 cases had a high expression of ICOS; ICOSL expression was low in 20 cases and high in 24 cases. According to the International Association for the Study of Lung Cancer (8th edition), phase I lesions were detected in 21 cases, phase II lesions in 15 cases, and phase III lesions in 18 cases. The median survival time of all patients was 44.5 months, and the median disease-free survival was 32 months. Univariate analysis showed that the factors significantly associated with overall survival were tumor size, regional lymph node involvement, stage, and expression level of ICOS/ICOSL. Survival analysis using log-rank test indicated that the lower ICOS+ cell infiltration may predict poor prognosis, whereas lower ICOSL protein expression may be associated with better prognosis, but ICOSL data need further validation in larger samples due to inconsistency in TCGA mRNA prediction. ICOS/ICOSL might be associated with prognosis of lung cancer, and ICOS and its ligand may be potential therapeutic targets in non-small cell lung cancer.
Sections du résumé
BACKGROUND
Immunotherapy has become the fastest-adopting treatment paradigm for lung cancer with improved survival. By binding with its ligand (inducible T-cell co-stimulator and its ligand [ICOSL]), an inducible T-cell co-stimulator (ICOS) could contribute to reversing immunosuppression and improving immune response and thus be a potential target for cancer immunotherapy.
METHODS
We selected 54 formalin-fixed, paraffin-embedded tumor tissues from cases with stage I-III lung adenocarcinoma cancer. Immunohistochemical expression of ICOS and ICOSL was evaluated. The correlation with clinical parameters in Chinese patients was also compared with TCGA results.
RESULTS
The positive rates of ICOS and ICOSL were 68% and 81.5%, respectively, in lung tumor tissues. Of these, 9 cases had a low expression of ICOS, and 22 cases had a high expression of ICOS; ICOSL expression was low in 20 cases and high in 24 cases. According to the International Association for the Study of Lung Cancer (8th edition), phase I lesions were detected in 21 cases, phase II lesions in 15 cases, and phase III lesions in 18 cases. The median survival time of all patients was 44.5 months, and the median disease-free survival was 32 months. Univariate analysis showed that the factors significantly associated with overall survival were tumor size, regional lymph node involvement, stage, and expression level of ICOS/ICOSL. Survival analysis using log-rank test indicated that the lower ICOS+ cell infiltration may predict poor prognosis, whereas lower ICOSL protein expression may be associated with better prognosis, but ICOSL data need further validation in larger samples due to inconsistency in TCGA mRNA prediction.
CONCLUSION
ICOS/ICOSL might be associated with prognosis of lung cancer, and ICOS and its ligand may be potential therapeutic targets in non-small cell lung cancer.
Identifiants
pubmed: 37850501
doi: 10.1002/ame2.12355
pmc: PMC10614122
doi:
Substances chimiques
Inducible T-Cell Co-Stimulator Protein
0
Ligands
0
Inducible T-Cell Co-Stimulator Ligand
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
464-473Informations de copyright
© 2023 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
Références
Cancer Res. 2010 Dec 1;70(23):9581-90
pubmed: 21098714
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Front Immunol. 2020 Aug 28;11:2104
pubmed: 32983168
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Curr Protein Pept Sci. 2018;19(11):1107-1113
pubmed: 29879883
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Animal Model Exp Med. 2021 Mar 29;4(2):87-103
pubmed: 34179717
Clin Cancer Res. 2022 Dec 1;28(23):5136-5148
pubmed: 36166003
Blood. 2013 Jan 31;121(5):734-44
pubmed: 23223433
Cancer Res. 1986 Oct;46(10):5419-25
pubmed: 3756890
Int J Gen Med. 2022 Apr 06;15:3739-3751
pubmed: 35418779
PeerJ. 2019 May 16;7:e6903
pubmed: 31143539
Animal Model Exp Med. 2023 Oct;6(5):464-473
pubmed: 37850501
J Thorac Oncol. 2018 Jun;13(6):779-791
pubmed: 29526824
Animal Model Exp Med. 2021 Mar 23;4(2):138-150
pubmed: 34179721
Asian Pac J Cancer Prev. 2014;15(8):3513-8
pubmed: 24870749
Cancer Commun (Lond). 2022 Oct;42(10):937-970
pubmed: 36075878
Oncoimmunology. 2013 Mar 1;2(3):e23185
pubmed: 23802069
Clin Cancer Res. 2017 Dec 15;23(24):7474-7482
pubmed: 28951518
Cancer Res. 2020 Jul 15;80(14):3023-3032
pubmed: 32156777
Biomed Pharmacother. 2017 Nov;95:55-61
pubmed: 28826097
Oncoimmunology. 2016 Mar 10;5(5):e1141857
pubmed: 27467961
Nat Commun. 2020 Oct 8;11(1):5066
pubmed: 33033255
J Drug Target. 2023 Aug;31(7):700-713
pubmed: 37417910
Biochem Biophys Rep. 2020 Sep 10;24:100803
pubmed: 32984557
Animal Model Exp Med. 2022 Sep;5(3):217-226
pubmed: 35713208
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Int J Cancer. 2017 Feb 1;140(3):686-695
pubmed: 27756099
Blood. 2013 Oct 17;122(16):2856-63
pubmed: 24004665
Commun Biol. 2020 Oct 26;3(1):615
pubmed: 33106594
Cancer Res. 2012 Oct 15;72(20):5240-9
pubmed: 22850422
Animal Model Exp Med. 2022 Apr;5(2):108-119
pubmed: 35412027
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
ESMO Open. 2020 Jan;5(1):
pubmed: 32516116